{"pmid":32394344,"title":"COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.","text":["COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.","INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.","Infection","Harter, Georg","Spinner, Christoph D","Roider, Julia","Bickel, Markus","Krznaric, Ivanka","Grunwald, Stephan","Schabaz, Farhad","Gillor, Daniel","Postel, Nils","Mueller, Matthias C","Muller, Markus","Romer, Katja","Schewe, Knud","Hoffmann, Christian","32394344"],"abstract":["INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART."],"journal":"Infection","authors":["Harter, Georg","Spinner, Christoph D","Roider, Julia","Bickel, Markus","Krznaric, Ivanka","Grunwald, Stephan","Schabaz, Farhad","Gillor, Daniel","Postel, Nils","Mueller, Matthias C","Muller, Markus","Romer, Katja","Schewe, Knud","Hoffmann, Christian"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394344","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s15010-020-01438-z","keywords":["aids","antiretroviral therapy","covid-19","hiv infection","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666627827890388992,"score":9.490897,"similar":[{"pmid":32469614,"title":"A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.","text":["A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.","The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm(3) and suppressed HIV viral loads at the time of COVID-19 diagnosis. All five patients were hospitalized, two required supplemental oxygen, and none required mechanical ventilation. Four patients were treated with azithromycin and a cephalosporin and two were also treated with hydroxychloroquine. The median length of stay was 3 days (range 2-7). All patients recovered. More research is needed to understand the risks of COVID-19 among PLWH and the impact of ART on outcomes for patients with COVID-19.","AIDS Patient Care STDS","Ridgway, Jessica P","Farley, Brianna","Benoit, Jean-Luc","Frohne, Christopher","Hazra, Aniruddha","Pettit, Natasha","Pho, Mai","Pursell, Kenneth","Saltzman, Jina","Schmitt, Jessica","Uvin, Arno Ziggy","Pitrak, David","McNulty, Moira","32469614"],"abstract":["The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm(3) and suppressed HIV viral loads at the time of COVID-19 diagnosis. All five patients were hospitalized, two required supplemental oxygen, and none required mechanical ventilation. Four patients were treated with azithromycin and a cephalosporin and two were also treated with hydroxychloroquine. The median length of stay was 3 days (range 2-7). All patients recovered. More research is needed to understand the risks of COVID-19 among PLWH and the impact of ART on outcomes for patients with COVID-19."],"journal":"AIDS Patient Care STDS","authors":["Ridgway, Jessica P","Farley, Brianna","Benoit, Jean-Luc","Frohne, Christopher","Hazra, Aniruddha","Pettit, Natasha","Pho, Mai","Pursell, Kenneth","Saltzman, Jina","Schmitt, Jessica","Uvin, Arno Ziggy","Pitrak, David","McNulty, Moira"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469614","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1089/apc.2020.0103","keywords":["covid-19","hiv","coinfection"],"locations":["African American","Chicago","Illinois"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668167109881888768,"score":393.87042},{"pmid":32472138,"title":"Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19.","text":["Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19.","We describe the characteristics of 31 people living with HIV (PLWH) hospitalized for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. All patients were on antiretroviral therapy and virologically suppressed at the time of admission. Clinical course and outcomes were similar to those reported in other hospitalized cohorts.","Clin Infect Dis","Shalev, Noga","Scherer, Matthew","LaSota, Elijah D","Antoniou, Pantelis","Yin, Michael T","Zucker, Jason","Sobieszczyk, Magdalena E","32472138"],"abstract":["We describe the characteristics of 31 people living with HIV (PLWH) hospitalized for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. All patients were on antiretroviral therapy and virologically suppressed at the time of admission. Clinical course and outcomes were similar to those reported in other hospitalized cohorts."],"journal":"Clin Infect Dis","authors":["Shalev, Noga","Scherer, Matthew","LaSota, Elijah D","Antoniou, Pantelis","Yin, Michael T","Zucker, Jason","Sobieszczyk, Magdalena E"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472138","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/cid/ciaa635","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668255193342410752,"score":284.17145},{"pmid":32303925,"title":"The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective.","text":["The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective.","The emergence of the novel coronavirus disease known as COVID-19 creates another health burden for people living with HIV (PLWH) who face multiple morbidities and may be at heightened risk for severe physical health illness from COVID-19. Our abilities to address these morbidities in PLWH must be considered alongside the socially-produced burdens that both place this population at risk for COVID-19 and heighten the likelihood of adverse outcomes. These burdens can affect the physical, emotional, and social well-being of PLWH and interfere with the delivery of effective healthcare and access to HIV treatment. We posit that a syndemic framework can be used to conceptualize the potential impact of COVID-19 among PLWH to inform the development of health programming services.","AIDS Behav","Shiau, Stephanie","Krause, Kristen D","Valera, Pamela","Swaminathan, Shobha","Halkitis, Perry N","32303925"],"abstract":["The emergence of the novel coronavirus disease known as COVID-19 creates another health burden for people living with HIV (PLWH) who face multiple morbidities and may be at heightened risk for severe physical health illness from COVID-19. Our abilities to address these morbidities in PLWH must be considered alongside the socially-produced burdens that both place this population at risk for COVID-19 and heighten the likelihood of adverse outcomes. These burdens can affect the physical, emotional, and social well-being of PLWH and interfere with the delivery of effective healthcare and access to HIV treatment. We posit that a syndemic framework can be used to conceptualize the potential impact of COVID-19 among PLWH to inform the development of health programming services."],"journal":"AIDS Behav","authors":["Shiau, Stephanie","Krause, Kristen D","Valera, Pamela","Swaminathan, Shobha","Halkitis, Perry N"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303925","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s10461-020-02871-9","keywords":["antivirals","covid-19","hiv","health care","psychosocial burdens","syndemic"],"topics":["Prevention"],"weight":1,"_version_":1666138491058126849,"score":270.35733},{"pmid":32479865,"pmcid":"PMC7258847","title":"Lack of Antiviral Activity of Darunavir against SARS-CoV-2.","text":["Lack of Antiviral Activity of Darunavir against SARS-CoV-2.","OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100muM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50=0.38muM). CONCLUSIONS: Overall, the data do not support the use of DRV for treatment of COVID-19.","Int J Infect Dis","De Meyer, Sandra","Bojkova, Denisa","Cinatl, Jindrich","Van Damme, Ellen","Meng, Christophe Buyck","Van Loock, Marnix","Woodfall, Brian","Ciesek, Sandra","32479865"],"abstract":["OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100muM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50=0.38muM). CONCLUSIONS: Overall, the data do not support the use of DRV for treatment of COVID-19."],"journal":"Int J Infect Dis","authors":["De Meyer, Sandra","Bojkova, Denisa","Cinatl, Jindrich","Van Damme, Ellen","Meng, Christophe Buyck","Van Loock, Marnix","Woodfall, Brian","Ciesek, Sandra"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479865","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.085","keywords":["covid-19","darunavir","sars-cov-2","in vitro"],"e_drugs":["remdesivir","Cobicistat","Darunavir"],"topics":["Treatment"],"weight":1,"_version_":1668532089553682432,"score":211.79684},{"pmid":32492753,"title":"Recovery from COVID-19 following Hepatitis C, Human Immunodeficiency Virus Infection and Liver Transplantation.","text":["Recovery from COVID-19 following Hepatitis C, Human Immunodeficiency Virus Infection and Liver Transplantation.","Immunosuppression and frequent comorbidities in transplant recipients potentially increase the risk of fatal outcomes of pandemic coronavirus disease 2019 (COVID-19) [1]. A 1965 born male had suffered from haemophilia A. In the nineteen-seventies, he acquired hepatitis C virus (HCV) infection, probably via factor VIII supplementation, and in 1985 human immunodeficiency virus (HIV) infection. Interferon-based HCV therapy resulted in a sustained virological response. Antiviral treatment with emtricitabine/tenofovir alafenamide/rilpivirin for HIV is ongoing since 2016. HIV suppression with repeatedly negative PCR results has been achieved.","Am J Transplant","Muller, Helmut","Kniepeiss, Daniela","Stauber, Rudolf","Schrem, Harald","Rauter, Markus","Krause, Robert","Schemmer, Peter","32492753"],"abstract":["Immunosuppression and frequent comorbidities in transplant recipients potentially increase the risk of fatal outcomes of pandemic coronavirus disease 2019 (COVID-19) [1]. A 1965 born male had suffered from haemophilia A. In the nineteen-seventies, he acquired hepatitis C virus (HCV) infection, probably via factor VIII supplementation, and in 1985 human immunodeficiency virus (HIV) infection. Interferon-based HCV therapy resulted in a sustained virological response. Antiviral treatment with emtricitabine/tenofovir alafenamide/rilpivirin for HIV is ongoing since 2016. HIV suppression with repeatedly negative PCR results has been achieved."],"journal":"Am J Transplant","authors":["Muller, Helmut","Kniepeiss, Daniela","Stauber, Rudolf","Schrem, Harald","Rauter, Markus","Krause, Robert","Schemmer, Peter"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492753","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16107","locations":["VIII"],"topics":["Case Report"],"weight":1,"_version_":1668623433700737025,"score":209.24156}]}